Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Quarterly results
Appointed director
Surface Oncology, Inc. (SURF) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 8-K Quarterly results
07/07/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
07/03/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION",
"Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm",
"Financial Statements and Supplementary Data",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations"
06/16/2023 8-K Amended existing or entered into new employment agreement with an officer
Docs: "Agreement and Plan of Merger, by and among Surface Oncology, Inc., Coherus BioSciences, Inc., Crimson Merger Sub I, Inc. and Crimson Merger Sub II, LLC, (Form of CVR Agreement included as Exhibit A thereto)",
"Form of Executive Agreement Amendment",
"Form of C-Suite Executive Agreement Amendment",
"Form of Retention Agreement",
"Coherus to Acquire Surface Oncology"
05/04/2023 8-K Quarterly results
03/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "EX-99.1`"
02/10/2023 8-K Quarterly results
01/12/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/02/2022 8-K Quarterly results
09/23/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Second Amendment to Loan and Security Agreement, by and between Surface Oncology, Inc. and K2 HealthVentures LLC",
"Second Amendment to Loan and Security Agreement, by and between Surface Oncology, Inc. and K2 HealthVentures LLC"
08/03/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Surface Oncology Reports Financial Results and Business Highlights for Second Quarter 2022 – SRF388 clinical data presented at 2022 ASCO Annual Meeting demonstrated monotherapy responses in two different indications, combination activity and notable disease stabilization –"
06/29/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/02/2022 8-K Quarterly results
12/15/2021 8-K Quarterly results
12/06/2021 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2021 Company to initiate randomized Phase 2 clinical study evaluating SRF388 in combination with Roche’s atezolizumab and bevacizumab, in patients with treatment-naïve HCC"
10/04/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "First Amendment to Loan and Security Agreement, by and among Surface Oncology, Inc. and, K2 HealthVentures LLC and Ankura Trust Company, LLC †",
"Surface Oncology Announces New Randomized Phase 2 Clinical Study Evaluating SRF388 in Patients with First-Line Hepatocellular Carcinoma in Clinical Collaboration with Roche"
07/08/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 6, 2021 SURFACE ONCOLOGY, INC. Delaware 001-38459 46-5543980 50 Hampshire Street, 8th Floor Cambridge, MA 02139 Registrant's telephone number, including area code: 714-4096 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement c...",
"Surface Oncology Appoints Denice Torres to Board of Directors Brings 25 years of strategic leadership experience across healthcare CAMBRIDGE, Mass., July 8, 2021 — Surface Oncology , a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Denice Torres will join the company's board of directors. Ms. Torres has over 25 years of executive leadership experience in healthcare across the consumer, biopharmaceutical and medical device sectors. “I am thrilled to welcome Denice to the Surface board. She shares our commitment to bring transformational treatments to patients living with cancer,” said Rob Ross, M.D., chief executive officer at Surface. “She is an insightful leader in biopharma, with significant e..."
06/10/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
05/03/2021 8-K Quarterly results
04/27/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
12/17/2020 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 16, 2020 SURFACE ONCOLOGY, INC. Delaware 001-38459 46-5543980 50 Hampshire Street, 8th Floor Cambridge, MA 02139 Registrant's telephone number, including area code: 714-4096 Not Applicable Former name or former address, if changed since last report Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communicat...",
"LICENSE AGREEMENT",
"Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program"
11/25/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Surface Oncology to Participate in the 3rd Annual Evercore ISI HealthCONx Conference"
11/13/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination and Expansion Stages of Ongoing Phase 1 Clinical Trials Both programs have successfully escalated to dose levels demonstrating pharmacodynamic activity without dose-limiting toxicities"
11/12/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy